Cent Eur J Public Health 2026, 34(1):22-27 | DOI: 10.21101/cejph.a8538

Early diagnosis and risk groups: comorbidities in newly diagnosed adults with HIV in Turkey

ªemsi Nur Karabela, Fatma Bayrak Erdem, Esra Canbolat Ünlü, Beyza Kaplan Yapar, Sevtap ªenoğlu, Habip Gedik, Kadriye Kart Yaºar
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

Objectives: This study aimed to identify factors contributing to the early diagnosis of HIV in Turkey, with a particular focus on high-risk populations, comorbid conditions, and temporal trends. It also evaluated whether initial clinical findings could inform the expansion of screening strategies.

Methods: A retrospective analysis was conducted on 1,703 individuals living with human immunodeficiency virus (HIV) who attended our clinic between 2004 and 2023. Patients were grouped into five-year intervals and assessed based on demographic characteristics, reasons for testing, and reported comorbidities.

Results: Among the participants, 90.3% were males, with a mean age of 36.6 years. Of those who disclosed their sexual orientation, 46.8% identified as heterosexual. Common comorbidities included anal region disorders, cardiovascular and pulmonary diseases, diabetes, and syphilis. HBsAg positivity was 5%, and anti-HCV positivity was 0.86%. Nearly half of the patients (48.6%) were asymptomatic at the time of diagnosis. Physician-initiated testing and routine screenings played a significant role in early detection.

Conclusion: Early diagnosis of HIV is essential for reducing transmission and improving patient outcomes. Screening programmes should be expanded to include not only high-risk groups but also sexually active individuals presenting with relevant clinical symptoms. Public health efforts must address stigma and improve access to HIV testing to optimize early detection and treatment.

Keywords: human immunodeficiency virus, early diagnosis, HIV testing strategies, high-risk populations, comorbidities

Received: January 29, 2025; Revised: November 3, 2025; Accepted: November 3, 2025; Published: March 31, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karabela ªN, Bayrak Erdem F, Canbolat Ünlü E, Kaplan Yapar B, ªenoğlu S, Gedik H, Kart Yaºar K. Early diagnosis and risk groups: comorbidities in newly diagnosed adults with HIV in Turkey. Cent Eur J Public Health. 2026;34(1):22-27. doi: 10.21101/cejph.a8538.
Download citation

References

  1. Republic of Türkiye Ministry of Health, General Directorate of Public Health, Department of Infectious Diseases and Early Warning. [HIV-AIDS Statistics, 2025] [Internet]. 2025 [cited 2025 Nov 1]. Available from: https://hsgm.saglik.gov.tr/tr/dokumanlar-bulasicihastaliklar/bulasici-istatistikler.html. Turkish.
  2. Yurdakul ª, Mehmet N. Epidemiological studies on HIV/AIDS in Türkiye: a review. ESTUDAM Public Health J. 2023;8(1):80-6. Go to original source...
  3. Onal U, Akalin H. Opportunistic infections among Human Immunodeficiency Virus (HIV) infected patients in Turkey: a systematic review. Infect Dis Clin Microbiol. 2023;5(2):82-93. Go to original source... Go to PubMed...
  4. Liu T, Zhang S, Yang L, Peng L, Tang S, Li W, et al. Epidemiological and typing features of HPV co-infections in MSM with mpox: a hospital-based prospective study. J Infect Public Health. 2024;17(12):102586. doi: 10.1016/j.jiph.2024.102586. Go to original source... Go to PubMed...
  5. Oko-Jaja RI, Awopeju ATO. Pattern of comorbidities among highly active anti‑retroviral therapy‑naive HIV‑infected adult Nigerian patients at initial diagnosis. P H Med J. 2017;11(1):34-7. Go to original source...
  6. Senoglu S, Yeºilbağ Z, Kumbasar Karaosmanoğlu H, Aydin O. Epidemiological differences and risk factors for hospitalization in people living with HIV in Istanbul, Turkey. Int J STD AIDS. 2019;30(13):1284-9. Go to original source... Go to PubMed...
  7. Erbaydar T, Erbaydar NP. Status of HIV/AIDS epidemic in Turkey. Acta Medica. 2012;43(1):19-24.
  8. Tok D, Turhan V, Ozenc S, Karagoz E, Mert G. Prevalence of HIV infection in young male candidates scheduled for military recruitment and whole population in Turkey. Med Sci Discov. 2015;2(6):328-33. Go to original source...
  9. Abana CZY, Kushitor DK, Asigbee TW, Parbie PK, Ishikawa K, Kiyono H, et al. Community based multi-disease health screening as an opportunity for early detection of HIV cases and linking them to care. BMC Public Health. 2023;23(1):1051. doi: 10.1186/s12889-023-15948-6. Go to original source... Go to PubMed...
  10. Lo T, Fang CT, Lee YY, Shih CC, Chu FY, Wang JD. Early HIV diagnosis enhances quality-adjusted life expectancy of men who have sex with men living with HIV: a population-based cohort study in Taiwan. J Microbiol Immunol Infect. 2024;57(1):85-96. Go to original source... Go to PubMed...
  11. US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(23):2326-36. Go to original source... Go to PubMed...
  12. Shah I, Poojari V. Clinical algorithm for screening of HIV among high-risk children - need of the hour! Indian Pediatr. 2020;57(7):611-2. Go to original source...
  13. Bouabida K, Chaves BG, Anane E. Challenges and barriers to HIV care engagement and care cascade: viewpoint. Front Reprod Health. 2023;5:1201087. doi: 10.3389/frph.2023.1201087. Go to original source... Go to PubMed...
  14. Vaz-Pinto I, Gorgulho A, Esteves C, Guimarães M, Castro V, Carrodeguas A, et al. Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments. HIV Med. 2022;23(11):1153-62. Go to original source... Go to PubMed...
  15. Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16(6):584-9. Go to original source... Go to PubMed...
  16. Kuºcu EG, Aliravci ID, Kiriºci Ö, Vurucu S. Two-center comparison of viral hepatitis A, B, C seroprevalence among the 18-25 age group. KSU Med J. 2024;19(1):89-94. Go to original source...
  17. Özkan H. Epidemiology of chronic hepatitis B in Turkey. Euroasian J Hepatogastroenterol. 2018;8(1):73-4. Go to original source... Go to PubMed...
  18. Juganariu G, Mihalache D, Miftode E, Teodor A, Teodor D, Manciuc C, et al. Characteristics of co infection with hepatitis B virus among Romanian patients infected with human immunodeficiency virus. Rev Med Chir Soc Med Nat Iasi. 2014;118(2):339-45.
  19. El-Ghitany EM, Farghaly AG, Alkassabany YM. Prevalence and risk factors of HBV and HCV co-infection among people living with HIV in an Egyptian setting. Curr HIV Res. 2021;19(6):514-24. Go to original source... Go to PubMed...
  20. Ünlü G, Yildiz Y, Ören MM, Çabalak M, Mete Ö, Kömür S, et al. Occult hepatitis B infection in Turkish HIV-infected patients: a multicentre, retrospective, cross-sectional study, Schindler study. Int J Clin Pract. 2021;75(9):e14358. doi: 10.1111/ijcp.14358. Go to original source... Go to PubMed...
  21. Aydin OA, Yemisen M, Karaosmanoglu HK, Sargin F, Gunduz A, Ceylan B, et al. Low prevalence of hepatitis C virus infection among HIV-positive patients: data from a large-scale cohort study in Istanbul, Turkey. Hepat Mon. 2014;14(8):e18128. doi: 10.5812/hepatmon.18128. Go to original source... Go to PubMed...
  22. Bilek HC, Deveci A, Tanyel EA. Seroprevalence of hepatitis A virus, hepatitis B virus, hepatitis C virus, and syphilis among human immunodeficiency virus-infected people at a university hospital, Turkey. Arch Med Sci. 2025;21(2):437-41
  23. Tedaldi E, Armon C, Li J, Mahnken J, Simoncini G, Palella F, et al. A heavy burden: preexisting physical and psychiatric comorbidities and differential increases among male and female participants after initiating antiretroviral therapy in the HIV outpatient study, 2008-2018. AIDS Res Hum Retroviruses. 2022;38(7):519-29. Go to original source... Go to PubMed...
  24. Urunova DM, Akhmedzhanova ZI. [Assessment of the comorbidity index in HIV-infected patients before ART]. J Infectology. 2022;14(4):94-101. Russian. Go to original source...
  25. De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, et al. Patterns of co-occurring comorbidities in people living with HIV. Open Forum Infect Dis. 2018;5(11):ofy272. doi: 10.1093/ofid/ofy272. Go to original source... Go to PubMed...
  26. Yeºilbağ Z, ªengül Eİ, ªenoğlu S, Aydin ÖA, Karaosmanoğlu HK. Co-medications and drug-drug interactions in people living with HIV in Turkey in the era of integrase inhibitors. Curr HIV Res. 2020;18(6):415-25.
  27. Righetto RC, Reis RK, Reinato LAF, Gir E. Comorbidities and co-infections in people living with HIV/AIDS. Rev Rene. 2014;15(6):942-8. Go to original source...
  28. Seethalakshmi H, Sharma R, Bharathraj KC, Nayak P, Shreyas K. Prescription pattern and management of comorbid conditions of HIV-positive patients in a tertiary care teaching hospital: a retrospective study. Authorea [Preprint]. 2024 Jan 31:711395. doi: 10.22541/au.170667742.23070968/v1. Go to original source...
  29. Jimenez HR, Bover Manderski MT, Natali KM, Boachie N, Suh JS. Prevalence of comorbidities and polypharmacy in a historically minoritized community and their impact on virologic suppression in persons with HIV. AIDS Patient Care STDs. 2023;37(6):297-305. Go to original source... Go to PubMed...